Glycogen synthase kinase-3β: Variation over time and the possible association with mood and cognition in healthy individuals
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Glycogen synthase kinase-3β : Variation over time and the possible association with mood and cognition in healthy individuals. / Munkholm, Klaus; Lenskjold, Toke; Jacoby, Anne Sophie; Miskowiak, Kamilla Woznica; Vinberg, Maj; Joaquim, Helena Giroud Passarelli; Talib, Leda Leme; Gattaz, Wagner Farid; Kessing, Lars Vedel.
I: Neuropsychobiology, Bind 73, Nr. 2, 2016, s. 108-115.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Glycogen synthase kinase-3β
T2 - Variation over time and the possible association with mood and cognition in healthy individuals
AU - Munkholm, Klaus
AU - Lenskjold, Toke
AU - Jacoby, Anne Sophie
AU - Miskowiak, Kamilla Woznica
AU - Vinberg, Maj
AU - Joaquim, Helena Giroud Passarelli
AU - Talib, Leda Leme
AU - Gattaz, Wagner Farid
AU - Kessing, Lars Vedel
PY - 2016
Y1 - 2016
N2 - Evidence indicates a role for glycogen synthase kinase-3β (GSK-3β) in the pathophysiology of mood disorders and in cognitive disturbances; however, the natural variation in GSK-3β activity over time is unknown. We aimed to investigate GSK-3β activity over time and its possible correlation with emotional lability, subjective mood fluctuations and cognitive function in healthy individuals. Thirty-seven healthy subjects were evaluated with neuropsychological tests and blood samples at baseline and 12-week follow-up. Total GSK-3β and serine-9-phosphorylated GSK-3β in peripheral blood mononuclear cells were quantitated using enzyme immunometric assays. The activity of GSK-3β (serine-9-phosphorylated GSK-3β/total GSK-3β) was lower at baseline compared with follow-up. No significant mean change over time was observed in levels of total GSK-3β and serine-9-phosphorylated GSK-3β. Exploratory analysis revealed lower activity of GSK-3β in spring and summer compared with the fall season. No correlation was observed between GSK-3β activity and emotional lability, subjective mood fluctuations or cognitive function. The results suggest that intra- and interindividual variation in GSK-3β activity over time could contribute to the heterogeneity of findings in clinical studies. The stability of GSK-3β activity and the role of potential moderators of GSK-3β activity warrant further investigation. Clinical studies of GSK-3β should consider including repeated measures of both cases and healthy individuals.
AB - Evidence indicates a role for glycogen synthase kinase-3β (GSK-3β) in the pathophysiology of mood disorders and in cognitive disturbances; however, the natural variation in GSK-3β activity over time is unknown. We aimed to investigate GSK-3β activity over time and its possible correlation with emotional lability, subjective mood fluctuations and cognitive function in healthy individuals. Thirty-seven healthy subjects were evaluated with neuropsychological tests and blood samples at baseline and 12-week follow-up. Total GSK-3β and serine-9-phosphorylated GSK-3β in peripheral blood mononuclear cells were quantitated using enzyme immunometric assays. The activity of GSK-3β (serine-9-phosphorylated GSK-3β/total GSK-3β) was lower at baseline compared with follow-up. No significant mean change over time was observed in levels of total GSK-3β and serine-9-phosphorylated GSK-3β. Exploratory analysis revealed lower activity of GSK-3β in spring and summer compared with the fall season. No correlation was observed between GSK-3β activity and emotional lability, subjective mood fluctuations or cognitive function. The results suggest that intra- and interindividual variation in GSK-3β activity over time could contribute to the heterogeneity of findings in clinical studies. The stability of GSK-3β activity and the role of potential moderators of GSK-3β activity warrant further investigation. Clinical studies of GSK-3β should consider including repeated measures of both cases and healthy individuals.
KW - Biomarker
KW - Bipolar disorder
KW - Peripheral blood
U2 - 10.1159/000444489
DO - 10.1159/000444489
M3 - Journal article
C2 - 27003416
AN - SCOPUS:84961393803
VL - 73
SP - 108
EP - 115
JO - Neuropsychobiology
JF - Neuropsychobiology
SN - 0302-282X
IS - 2
ER -
ID: 228245672